Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer.
Fucikova J, Podrazil M, Jarolim L, Bilkova P, Hensler M, Becht E, Gasova Z, Klouckova J, Kayserova J, Horvath R, Fialova A, Vavrova K, Sochorova K, Rozkova D, Spisek R, Bartunkova J. Fucikova J, et al. Among authors: bartunkova j. Cancer Immunol Immunother. 2018 Jan;67(1):89-100. doi: 10.1007/s00262-017-2068-x. Epub 2017 Sep 25. Cancer Immunol Immunother. 2018. PMID: 28948333 Free PMC article. Clinical Trial.
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.
Podrazil M, Horvath R, Becht E, Rozkova D, Bilkova P, Sochorova K, Hromadkova H, Kayserova J, Vavrova K, Lastovicka J, Vrabcova P, Kubackova K, Gasova Z, Jarolim L, Babjuk M, Spisek R, Bartunkova J, Fucikova J. Podrazil M, et al. Among authors: bartunkova j. Oncotarget. 2015 Jul 20;6(20):18192-205. doi: 10.18632/oncotarget.4145. Oncotarget. 2015. PMID: 26078335 Free PMC article. Clinical Trial.
Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial.
Rob L, Cibula D, Knapp P, Mallmann P, Klat J, Minar L, Bartos P, Chovanec J, Valha P, Pluta M, Novotny Z, Spacek J, Melichar B, Kieszko D, Fucikova J, Hrnciarova T, Korolkiewicz RP, Hraska M, Bartunkova J, Spisek R. Rob L, et al. Among authors: bartunkova j. J Immunother Cancer. 2022 Jan;10(1):e003190. doi: 10.1136/jitc-2021-003190. J Immunother Cancer. 2022. PMID: 34992091 Free PMC article. Clinical Trial.
163 results